A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

NCT01493557 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1067

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: pantoprazole
DRUG: Pradaxa (dabigatran etexilate)
DRUG: Pradaxa, within 30 minutes after a meal
DRUG: Pradaxa (dabigatran etexilate)

Sponsor

Boehringer Ingelheim